Chester County News and Community Website
BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced its financial results for the second quarter ending June 30, 2024, alongside notable advancements in its product pipeline and strategic initiatives.
Virpax Pharmaceuticals Reports Q2 2024 Financial Results and Strategic Progress Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) will participate in the Sidoti August Virtual Investor Conference. CEO Gerald W. Bruce and CFO Vinay Shah will present and host one-on-one …
Virpax Pharmaceuticals to Present at Sidoti August Virtual Investor Conference Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. announced it has regained compliance with Nasdaq’s minimum bid price requirement as of July 24, 2024. This achievement follows a formal notice from Nasdaq’s …
Virpax Pharmaceuticals Regains Nasdaq Compliance Read More BERWYN, PA — Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced positive results from a pilot study using a swine model for Probudur, its long-acting pain relief drug. Probudur, a liposomal …
Virpax Pharmaceuticals Reports Promising Results for Pain Relief Drug Read More BERWYN, PA — Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) recently released its financial results for the first quarter of 2024, revealing increased losses as the company advances its drug development programs.
Virpax Pharmaceuticals Reports Increased Losses Amid Promising Developments Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) has unveiled hopeful results from its Maximum Tolerated Dose (MTD) study of Probudur™, a long-acting pain management drug, in Sprague-Dawley rats. Probudur, …
Virpax Pharmaceuticals’ Probudur Shows Promising Results in Pain Management Study Read More BERWYN, PA — Recent developments have been flourishing for Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX). The Pennsylvania-based pharmaceutical innovator recently unveiled its financial records for 2023 and shared a series of …
Virpax Pharmaceuticals Set for Transformative Year with High Hopes for Non-Addictive Pain Management Solutions Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced initial positive results from a pilot study of its pain management drug candidate, Probudur™. The study was conducted under an …
Virpax Pharmaceuticals Reports Promising Results in Probudur Pilot Study Read More BERWYN, PA — In a recent Special Meeting of Shareholders, Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) revealed that its stockholders had given the green light for a reverse stock split. The …
Virpax Pharmaceuticals Shareholders Approve Reverse Stock Split Amid Nasdaq Compliance Efforts Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX), a company specializing in non-opioid pain management therapies, has announced significant changes to its leadership team amidst ongoing litigation. The company recently …
Virpax Pharmaceuticals Announces Leadership Changes; Gerald Bruce Appointed CEO, Dr. Eric Floyd Named Chairman Read More